Skip to main content
Premium Trial:

Request an Annual Quote

Broad Sequences More than 5,100 Human Exomes Using Improved Agilent SureSelect Kit

Premium

This article was originally published Aug. 25.

Agilent Technologies said last week that the Broad Institute has used a new version of its SureSelect Human All Exon target enrichment kit to sequence the exomes of more than 5,100 human samples.

Agilent launched the SureSelect Human All Exon v2 kit, which covers 38 megabases of sequence and is more comprehensive than the first version, commercially last week. Like the original version, it developed the kit in collaboration with the Broad, which has used it for several months in its production pipeline.

So far, the Broad has used the v2 kit to sequence the exomes of more than 5,100 human samples "from a variety of cancer and heritable disease studies," said Sheila Fisher, assistant director of technology development for the Broad's genome sequencing center, in a statement.

In addition, Agilent offers the SureSelect Human All Exon 50 Mb kit, which it developed with the Wellcome Trust Sanger Institute as part of the Gencode project and which it released commercially earlier this month (IS 8/10/2010).

The Scan

And a Fourth?

A fourth dose of the Pfizer-BioNTech SARS-CoV-2 vaccine in an Israeli study increased antibody levels but did not prevent Omicron variant infections, according to the Financial Times.

For Better Science Software

A virtual institute funded by former Google CEO Eric Schmidt's philanthropy aims to lure software engineers to academia, Science reports.

Recommendation Explanations

The New York Times writes that the US Centers for Disease Control and Prevention is straining to both make and explain decisions based on limited information.

Genome Research Papers on De Novo Mutation Rates, Polyploid Genotyping, Oncogene Epigenomic Translocation

In Genome Research this week: de novo mutations rates in hemoglobin subunits, analysis of variant calling methods for polyploid plants, and more.